Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study

2021 ◽  
Author(s):  
Gouranga Sarkar ◽  
Vijay B. Gaikwad ◽  
Aradhana Sharma ◽  
Swapan K. Halder ◽  
Darivemula A. Kumar ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Essential Hypertension ◽  
Coronary Artery ◽  
Stable Coronary Artery Disease ◽  
Fixed Dose Combination ◽  
Phase Iii ◽  
Fixed Dose ◽  
Phase Iii Study ◽  
Dose Combination ◽  
Artery Disease

scholarly journals Fixed-dose combination of ivabradine and metoprolol in a patient with stable coronary artery disease: a case report

2021 ◽  
Vol 26 (9) ◽  
pp. 4657
Author(s):  
A. M. Shimkevich
Keyword(s):  
Coronary Artery Disease ◽  
Case Report ◽  
Clinical Practice ◽  
Coronary Artery ◽  
Stable Coronary Artery Disease ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Actual Clinical Practice ◽  
Dose Combination ◽  
Artery Disease

This article discusses a case of using fixed-dose combination of ivabradine/metoprolol in actual clinical practice.

Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease

1994 ◽  
Vol 74 (7) ◽  
pp. 657-661 ◽  
Author(s):  
Shaun G. Goodman ◽  
Anatoly Langer ◽  
Sherri S. Durica ◽  
Gary E. Raskob ◽  
Philip C. Comp ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Low Dose ◽  
Stable Coronary Artery Disease ◽  
Dose Combination ◽  
Artery Disease

Ticagrelor in the management of coronary artery disease

2020 ◽  
Author(s):  
Krithika Loganath ◽  
Philip D Adamson ◽  
Alastair J Moss
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Stable Coronary Artery Disease ◽  
Phase Iii ◽  
Major Cardiovascular Events ◽  
Increased Risk ◽  
Effective Inhibition ◽  
Phase Iii Trials ◽  
Artery Disease ◽  
Orally Active

Ticagrelor is a potent and orally active P2Y12 inhibitor. Ticagrelor has been extensively tested in Phase II and Phase III trials in patients with coronary artery disease. The pharmacokinetics and pharmacodynamics of Ticagrelor result in more rapid and effective inhibition of platelet activation compared with other P2Y12 inhibitors. This has resulted in a reduction in recurrent major cardiovascular events in initial randomized controls trials comparing Ticagrelor with clopidogrel. More recently, clinical trials have investigated the use of Ticagrelor in patients with stable coronary artery disease and a high residual risk of coronary thrombotic events. In patients with stable coronary artery disease, the potent antiplatelet effect of Ticagrelor is counterbalanced by an increased risk of major bleeding. Further research is ongoing to determine the optimal duration of Ticagrelor therapy.

Sign in / Sign up

Export Citation Format

Share Document